Daniel H. Ahn, DO, and Stacey A. Cohen, MD, engage in a comprehensive discussion on recent findings from the GALAXY study in CIRCULATE-Japan.
FDA Approves Noninvasive Stool DNA Test for Colorectal Cancer Screening
Data from the BLUE-C trial support the approval of the Cologuard Plus test for colorectal cancer screening among at-risk individuals.
Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
Phase 3 KEYFORM-007 Misses Primary End Point in MSS mCRC
The fixed-dose combination of favezelimab and pembrolizumab did not show an improvement in overall survival compared with the standard of care in patients with metastatic CRC.
Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions
Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.
Non-Operative Management Does Not Compromise DRFS in pMMR Rectal Cancer
NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.
Ramucirumab Combo Shows No Significant OS Improvement in Metastatic CRC
Subgroup analysis in a phase 3 trial show OS benefits with the ramucirumab-based regimen in female patients and those with left-sided tumors.